Barclays Increases Humana (NYSE:HUM) Price Target to $253.00

Humana (NYSE:HUM) had its target price boosted by analysts at Barclays from $250.00 to $253.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s target price would suggest a potential downside of 2.96% from the company’s previous close.

Several other research firms have also recently weighed in on HUM. Truist Financial lowered their price target on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a report on Friday, October 11th. UBS Group lowered their target price on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. Sanford C. Bernstein raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target for the company in a research note on Tuesday, October 8th. Cantor Fitzgerald restated a “neutral” rating and set a $395.00 price objective on shares of Humana in a research report on Tuesday, October 1st. Finally, Leerink Partners lowered shares of Humana from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $315.48.

Humana Price Performance

Shares of NYSE:HUM opened at $260.71 on Thursday. The company has a 50 day moving average of $297.06 and a 200 day moving average of $334.38. The company has a current ratio of 1.76, a quick ratio of 1.66 and a debt-to-equity ratio of 0.67. The stock has a market cap of $31.39 billion, a P/E ratio of 23.09, a P/E/G ratio of 2.07 and a beta of 0.50. Humana has a 12 month low of $213.31 and a 12 month high of $527.18.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, sell-side analysts forecast that Humana will post 16.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Humana

A number of hedge funds have recently modified their holdings of the company. Swedbank AB grew its stake in shares of Humana by 3.0% in the third quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock worth $33,567,000 after purchasing an additional 3,085 shares during the last quarter. Heritage Oak Wealth Advisors LLC bought a new stake in shares of Humana in the 2nd quarter worth approximately $3,456,000. Mandatum Life Insurance Co Ltd increased its stake in shares of Humana by 115.4% during the third quarter. Mandatum Life Insurance Co Ltd now owns 14,000 shares of the insurance provider’s stock valued at $4,434,000 after buying an additional 7,500 shares during the period. APG Asset Management US Inc. raised its holdings in shares of Humana by 3.0% during the second quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock valued at $25,274,000 after acquiring an additional 1,955 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock worth $21,462,000 after acquiring an additional 264 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.